Skip to content

Fecal calprotectin guided referral strategy in children in primary care

Optimising management of children with chronic gastrointestinal symptoms: a randomised controlled trial evaluating the effect of a fecal calprotectin guided referral strategy on the referral rate in primary care

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON20247
Enrollment
406
Registered
2019-04-26
Start date
2019-10-22
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Interventions

The use of FCal POCT in primary care. The general practitioners will receive an online training with instructions on indication, execution, interpretation, communication, reporting and follow-up of FC

Sponsors

ZonMw
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: - children, aged 4 to 18 years, with - chronic diarrhoea (soft or watery stool, matching scores 5–7 of the Bristol Stool chart, for >2 weeks or >2 episodes of 3 days in the past 6 months) OR - recurrent abdominal pain (>2 episodes of 3 days in the past 6 months)

Exclusion criteria

Exclusion criteria: - a history of chronic organic gastrointestinal disease - an endoscopic evaluation, referral to specialist care or FCal result within the preceding 6 months - difficulty in understanding questionnaires due to cognitive impairment or language problems

Design outcomes

Primary

MeasureTime frame
Proportion referrals in children with chronic GI disorders within 6 months after initial presentation in primary care.

Secondary

MeasureTime frame
Parental concerns and satisfaction, impact of symptoms on daily functioning, quality of life, use of health services, and cost-effectiveness during 6 months follow-up.

Contacts

Public ContactGea Holtman

Department of General Practice and Elderly Care Medicine, University Medical Center Groningen, University of Groningen

g.a.holtman@umcg.nl0031642637125

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)